Jan 31, 2022 | Press Releases
Data from the Phase 1 “HIV Cure” Study as published in Nature Medicine showed that Anktivaä (N-803) stimulates latent HIV replication in CD4+ cells (the kick) and increases immune cell activation (the kill) Activated CD4, CD8, and NK immune cells are necessary for...
Jan 18, 2022 | Press Releases
Data show that ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine, is potentially effective in pancreatic cancer where very few treatment options exist Nant Cancer Vaccine therapy more than doubles median overall survival (OS) versus historical OS in...
Jan 12, 2022 | Press Releases
Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing Practices (cGMP) facility with clean rooms will expedite capabilities for...
Jan 4, 2022 | Press Releases
NK cells engineered with a high-affinity CD16 receptor have the potential to enhance monoclonal antibody therapeutic effects against cancer cells Combination monoclonal antibody therapy and CD16 NK-92 cell therapy patent term to 2036 CULVER CITY, Calif., January 4,...
Jan 3, 2022 | Press Releases
EMERYVILLE and CULVER CITY, Calif., January 3, 2022 — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, and ImmunityBio (Nasdaq: IBRX), a...
Dec 20, 2021 | Press Releases
Year-End Review: SISONKE Universal Boost COVID T-Cell vaccine trial initiates Phase 3 enrollment in South Africa in previously vaccinated participants Increased GMP manufacturing capacity for RNA, DNA, Subunit Proteins, and Adjuvants vaccine platforms in U.S., South...
